Your browser is no longer supported. Please, upgrade your browser.
IGMS IGM Biosciences, Inc. daily Stock Chart
IGM Biosciences, Inc.
Index- P/E- EPS (ttm)-1.77 Insider Own1.60% Shs Outstand30.49M Perf Week-0.40%
Market Cap2.18B Forward P/E- EPS next Y-3.17 Insider Trans0.00% Shs Float13.36M Perf Month14.20%
Income-53.30M PEG- EPS next Q-0.65 Inst Own56.60% Short Float5.57% Perf Quarter19.60%
Sales- P/S- EPS this Y-80.00% Inst Trans5.56% Short Ratio7.83 Perf Half Y116.14%
Book/sh7.35 P/B9.75 EPS next Y-17.00% ROA-25.70% Target Price79.00 Perf Year-
Cash/sh6.80 P/C10.53 EPS next 5Y- ROE-33.10% 52W Range16.10 - 80.55 Perf YTD87.76%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-11.05% Beta-
Dividend %- Quick Ratio28.20 Sales past 5Y- Gross Margin- 52W Low345.03% ATR5.15
Employees77 Current Ratio28.20 Sales Q/Q- Oper. Margin- RSI (14)55.57 Volatility6.77% 8.28%
OptionableNo Debt/Eq0.00 EPS Q/Q-123.60% Profit Margin- Rel Volume0.48 Prev Close72.17
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume95.08K Price71.65
Recom1.40 SMA203.84% SMA5013.99% SMA20066.13% Volume46,329 Change-0.72%
Jul-01-20Initiated H.C. Wainwright Buy $88
May-28-20Initiated SunTrust Buy $86
Apr-22-20Initiated Wedbush Outperform $73
Oct-14-19Initiated Stifel Buy $32
Oct-14-19Initiated Piper Jaffray Overweight $26
Oct-14-19Initiated Jefferies Buy $25
Oct-14-19Initiated Guggenheim Buy $30
Jun-28-20 05:58PM  
Jun-16-20 06:27AM  
May-28-20 07:00AM  
May-12-20 07:00AM  
May-07-20 04:03PM  
Apr-29-20 04:05PM  
Apr-03-20 07:00AM  
Mar-26-20 04:05PM  
Mar-19-20 07:00AM  
Mar-04-20 07:00AM  
Feb-06-20 07:00AM  
Jan-07-20 07:00AM  
Dec-22-19 01:29PM  
Nov-12-19 07:00AM  
Nov-07-19 05:04PM  
Nov-01-19 10:24AM  
Oct-02-19 07:00AM  
Sep-20-19 04:05PM  
Sep-18-19 11:03AM  
Sep-17-19 08:46PM  
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Keyt BruceChief Scientific OfficerJun 04Option Exercise3.342,9879,9844,000Jun 08 06:40 PM
BEHRENS M KATHLEENDirectorDec 09Buy24.8720,000497,31610,000Dec 11 07:04 PM